Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 27.71
- Piotroski Score 2.00
- Grade Buy
- Symbol (RVMD)
- Company Revolution Medicines, Inc.
- Price $56.71
- Changes Percentage (-0.12%)
- Change -$0.07
- Day Low $56.39
- Day High $57.41
- Year High $62.40
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/24/2025
- Fiscal Year End N/A
- Average Stock Price Target $60.50
- High Stock Price Target $82.00
- Low Stock Price Target $43.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.84
- Trailing P/E Ratio -10.51
- Forward P/E Ratio -10.51
- P/E Growth -10.51
- Net Income $-436,367,000
Income Statement
Quarterly
Annual
Latest News of RVMD
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Revolution Medicines, Inc. (RVMD): Among Hedge Funds' Top Biotech Stock Picks
A list of the 10 largest biotech hedge funds and their top stock picks was compiled, focusing on Revolution Medicines, Inc. (NASDAQ:RVMD) and its position among biotech stocks....
By Yahoo! Finance | 2 months ago -
Revolution Medicines, Inc. (RVMD) Stock Price, News, Quote & History - Yahoo Finance
Revolution Medicines, Inc. is a precision oncology company developing targeted therapies for RAS-addicted cancers. They have a pipeline of RAS(ON) inhibitors and companion inhibitors for combination t...
By Yahoo! Finance | 4 months ago -
Insider Sale: COO Margaret Horn Sells Shares of Revolution Medicines Inc (RVMD)
Margaret Horn, COO of Revolution Medicines Inc, sold 4,415 shares at $37.39 each, totaling 93,609 shares sold in a year....
By Yahoo! Finance | 5 months ago
